GAMMA Investing’s AgomAb Therapeutics NV AGMB Stock Holding History
Bought
Maintained
Sold
Other funds holding AGMB
SL
GAMMA Investing's AGMB Position: Q3 2026 in Review
GAMMA Investing increased its AgomAb Therapeutics NV (AGMB) stake by 3.9% in Q3 2026, buying an estimated $673 and bringing the position to 1,396 shares worth $15.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3092.
GAMMA Investing first reported a position in AGMB in Q2 2026 and has held it in 2 quarters since. The position peaked at $17.4K in Q2 2026. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.
- GAMMA Investing held 1,396 shares of AgomAb Therapeutics NV worth $15.5K as of Q3 2026.
- GAMMA Investing bought 52 AgomAb Therapeutics NV shares in Q3 2026, an estimated $673.
- AgomAb Therapeutics NV made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3092 holding.
- GAMMA Investing first reported a position in AgomAb Therapeutics NV in Q2 2026 and has held it in 2 quarters since.
- GAMMA Investing's AgomAb Therapeutics NV position peaked at $17.4K in Q2 2026.
- 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.
Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.